NasdaqCM - Delayed Quote USD

BioLineRx Ltd. (BLRX)

0.6116 +0.0363 (+6.31%)
At close: April 26 at 4:00 PM EDT
0.6200 +0.01 (+1.37%)
After hours: April 26 at 5:51 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,800.0000
4,800.0000
--
--
--
Cost of Revenue
3,692.0000
3,692.0000
--
--
--
Gross Profit
1,108.0000
1,108.0000
--
--
--
Operating Expense
44,100.0000
44,100.0000
29,157.0000
24,777.0000
22,927.0000
Operating Income
-42,992.0000
-42,992.0000
-29,157.0000
-24,777.0000
-22,927.0000
Net Non Operating Interest Income Expense
-162.0000
-162.0000
-1,118.0000
-729.0000
-1,256.0000
Other Income Expense
-17,461.0000
-17,461.0000
5,324.0000
-1,548.0000
-5,838.0000
Pretax Income
-60,615.0000
-60,615.0000
-24,951.0000
-27,054.0000
-30,021.0000
Net Income Common Stockholders
-60,614.0000
-60,614.0000
-24,951.0000
-27,054.0000
-30,021.0000
Diluted NI Available to Com Stockholders
-60,614.0000
-60,614.0000
-24,951.0000
-27,054.0000
-30,021.0000
Basic EPS
-0.90
-0.90
-0.45
-0.60
-1.80
Diluted EPS
-0.90
-0.90
-0.45
-0.60
-1.80
Basic Average Shares
64,224.3680
64,224.3680
51,597.1320
44,195.5800
16,856.2930
Diluted Average Shares
64,224.3680
64,224.3680
51,597.1320
44,195.5800
16,856.2930
Total Operating Income as Reported
-49,694.0000
-49,694.0000
-29,157.0000
-24,777.0000
-22,927.0000
Total Expenses
47,792.0000
47,792.0000
29,157.0000
24,777.0000
22,927.0000
Net Income from Continuing & Discontinued Operation
-60,614.0000
-60,614.0000
-24,951.0000
-27,054.0000
-30,021.0000
Normalized Income
-42,918.0000
-42,918.0000
-31,030.0000
-25,400.0000
-24,742.0000
Interest Income
2,007.0000
2,007.0000
694.0000
277.0000
236.0000
Interest Expense
2,144.0000
2,144.0000
1,786.0000
984.0000
1,470.0000
Net Interest Income
-162.0000
-162.0000
-1,118.0000
-729.0000
-1,256.0000
EBIT
-58,471.0000
-58,471.0000
-23,165.0000
-26,070.0000
-28,551.0000
EBITDA
-57,087.0000
-57,087.0000
-22,511.0000
-25,367.0000
-27,617.0000
Reconciled Cost of Revenue
2,659.0000
2,659.0000
--
--
--
Reconciled Depreciation
1,384.0000
1,384.0000
654.0000
703.0000
934.0000
Net Income from Continuing Operation Net Minority Interest
-60,614.0000
-60,614.0000
-24,951.0000
-27,054.0000
-30,021.0000
Total Unusual Items Excluding Goodwill
-17,696.0000
-17,696.0000
6,079.0000
-1,654.0000
-5,279.0000
Total Unusual Items
-17,696.0000
-17,696.0000
6,079.0000
-1,654.0000
-5,279.0000
Normalized EBITDA
-39,391.0000
-39,391.0000
-28,590.0000
-23,713.0000
-22,338.0000
12/31/2020 - 7/27/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PLX Protalix BioTherapeutics, Inc.
1.1500
-2.54%
 
ENLV Enlivex Therapeutics Ltd.
1.4400
-0.69%
 
CANF Can-Fite BioPharma Ltd.
1.9800
+3.13%
 
EVGN Evogene Ltd.
0.6251
-4.91%
 
KZR Kezar Life Sciences, Inc.
0.8049
+1.89%
 
CGEN Compugen Ltd.
1.9200
+1.05%
 
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%
 
OCUP Ocuphire Pharma, Inc.
1.6100
+4.89%
 
PLUR Pluri Inc.
5.36
+2.23%
 
CKPT Checkpoint Therapeutics, Inc.
1.4300
+0.70%